Contineum Therapeutics, Inc. Class A Common Stock (CTNM) financials · $429.6M cap
Lician Pro · $19.99/mo or $149/yrCompare AAPL vs MSFT
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) $429.6M cap.
| Line | FY2025 | FY2024 | Pro (1 older periods with Lician Pro) |
|---|---|---|---|
| Revenue | — | — | |
| Operating Income | −$68.06M | −$50.89M | |
| Net Income | −$59.98M | −$42.26M | |
| EPS (Diluted) | −$2.17 | −$2.18 | |
| Unlock 3 years of statements: Lician Pro $149/yr | |||
| Line | FY2025 | FY2024 | Pro (1 older periods with Lician Pro) |
|---|---|---|---|
| Total Assets | $276.64M | $212.85M | |
| Current Assets | $267.92M | $206.39M | |
| Cash & Equivalents | $75.60M | $21.94M | |
| PP&E | $830.00K | $989.00K | |
| Total Liabilities | $15.65M | $14.78M | |
| Current Liabilities | $9.74M | $9.97M | |
| Shareholders' Equity | $260.99M | $198.07M | |
| Retained Earnings | −$177.38M | −$117.40M |
| Line | FY2025 | FY2024 | Pro (1 older periods with Lician Pro) |
|---|---|---|---|
| Operating Cash Flow | −$55.31M | −$32.84M | |
| CapEx | $231.00K | $514.00K | |
| Investing Cash Flow | −$3.71M | −$69.74M | |
| Financing Cash Flow | $112.69M | $109.00M | |
| Net Change in Cash | $53.66M | $6.42M | |
| Free Cash Flow | −$55.54M | −$33.36M |
Source: Company filings with the SEC (EDGAR) · Latest period FY2025
FAQ
What is CTNM P/E and revenue?
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) $429.6M cap.
What is CTNM revenue?
CTNM income-statement cache has no revenue figure yet.
Is CTNM profitable?
Contineum Therapeutics, Inc. Class A Common Stock last cached net income is -$60.0M (FY2025).
What are CTNM total assets?
Contineum Therapeutics, Inc. Class A Common Stock last cached total assets are $276.6M (FY2025).
What is CTNM free cash flow?
Contineum Therapeutics, Inc. Class A Common Stock last cached free cash flow is -$55.5M (FY2025).
Not investment advice. Figures as reported in company filings, not a live feed.